KEAP1 and kidney disorder: In contrast, mild Nrf2 activation by genetic Keap1 knockdown (KD) or rodent tolerable bardoxolone methyl analog, CDDO-imidazolide (CDDO-Im), did not attenuate kidney disease progression in Alport mice, suggesting that strong Nrf2 activation is essential for clear therapeutic efficacy.